Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | PSEN1 | P49768 | 5/20 | 0.58 |
| ▸ | PSEN2 | P49810 | 5/20 | 0.58 |
| ▸ | APH1B | Q8WW43 | 5/20 | 0.58 |
| ▸ | NCSTN | Q92542 | 5/20 | 0.58 |
| ▸ | APH1A | Q96BI3 | 5/20 | 0.58 |
| ▸ | PSENEN | Q9NZ42 | 5/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 4/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL760988 | 0.87 | PSEN1 (0.59) | TSHRPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6853609 | 0.79 | PSEN1 (0.65) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL759041 | 0.77 | PSEN1 (0.84) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL758946 | 0.76 | PSEN1 (0.74) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL6852566 | 0.76 | PSEN1 (0.73) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL758647 | 0.75 | PSEN1 (0.67) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL6853837 | 0.75 | PSEN1 (0.73) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL761534 | 0.75 | PSEN1 (0.72) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL758934 | 0.74 | PSEN1 (1.00) | TSHRPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL758281 | 0.74 | PSEN1 (0.79) | TSHRPSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053165-A1 | Novel Phenyl Imidazoles and Phenyl Triazoles As Gamma-Secretase Modulators | PFIZER INC. (US) | 2012-03-01 | — | — | US | disclosed |
| EP-2403835-A1 | NOVEL PHENYL IMIDAZOLES AND PHENYL TRIAZOLES AS GAMMA-SECRETASE MODULATORS | Pfizer Inc. (US) | 2012-01-11 | — | — | EP | disclosed |
| WO-2010100606-A1 | NOVEL PHENYL IMIDAZOLES AND PHENYL TRIAZOLES AS GAMMA-SECRETASE MODULATORS | PFIZER INC. (US) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053165-A1 | Novel Phenyl Imidazoles and Phenyl Triazoles As Gamma-Secretase Modulators | BACE1, BACE2, PSEN1 | TSHR 3595/4885PSEN1 3/4885PSEN2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.